| Program | Target(s) | Indication(s) | Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Commercial rights |
|---|---|---|---|---|---|---|---|---|
| Firi-cel* (CRG-022) | CD22 | R/R LBCL - post CD19 CAR T |  | |||||
| Firi-cel* (CRG-022) | CD22 | LBCL - CAR T naïve(1) | | |||||
| Firi-cel* (CRG-022) | CD22 | Pediatric B-ALL | | |||||
| CRG-023 (tri-specific CAR T with CD2 co-stimulation) | CD19 CD20 CD22 |
B-cell malignancies | | |||||
(1) Based on data from the Phase 1 clinical trial conducted by Stanford and pending data from our ongoing Phase 2 trial in R/R LBCL – post CD19 CAR T we intend to discuss with the FDA initiation of a Phase 2 program in LBCL – CAR T naïve without completing earlier clinical trials in LBCL – CAR T naïve patients.
*firicabtagene autoleucel
